Tarsus Pharmaceuticals (NASDAQ:TARS) Lowered to Hold Rating by Zacks Research

Zacks Research downgraded shares of Tarsus Pharmaceuticals (NASDAQ:TARS) from a strong-buy rating to a hold rating in a research report report published on Wednesday,Zacks.com reports.

A number of other research firms have also recently issued reports on TARS. Guggenheim lifted their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. The Goldman Sachs Group restated a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Finally, Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.

Tarsus Pharmaceuticals Trading Up 4.4%

Shares of TARS opened at $75.87 on Wednesday. The business’s 50-day moving average price is $72.12 and its 200 day moving average price is $68.43. The stock has a market capitalization of $3.23 billion, a P/E ratio of -46.83, a P/E/G ratio of 1.05 and a beta of 0.57. Tarsus Pharmaceuticals has a 1-year low of $38.51 and a 1-year high of $85.25. The company has a current ratio of 3.85, a quick ratio of 4.25 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. Analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Insider Activity

In other news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the transaction, the chief executive officer owned 857,991 shares in the company, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the transaction, the insider directly owned 38,958 shares of the company’s stock, valued at $3,120,535.80. This trade represents a 15.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 8.97% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Seven Fleet Capital Management LP bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth about $368,000. Invesco Ltd. boosted its position in Tarsus Pharmaceuticals by 8.0% in the fourth quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock valued at $82,892,000 after buying an additional 75,351 shares in the last quarter. Mackenzie Financial Corp bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth about $202,000. XTX Topco Ltd grew its stake in Tarsus Pharmaceuticals by 270.3% during the fourth quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock worth $1,507,000 after buying an additional 13,438 shares during the last quarter. Finally, Squadron Capital Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth approximately $6,550,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target and reiterated an outperform view, signaling stronger institutional optimism about Tarsus’ longer‑term upside. Oppenheimer Issues Positive Forecast
• Positive Sentiment: Guggenheim bumped its price target to $90 and kept a buy rating, providing additional upward pressure on sentiment and implied valuation. Guggenheim $90 Price Target
• Neutral Sentiment: Tarsus announced management will participate in upcoming investor conferences, increasing visibility and giving investors more opportunities for management updates. Investor Conference Participation
• Neutral Sentiment: Media/analysis pieces are debating whether the market has rerated Tarsus after XDEMVY adoption headlines — useful context but not a direct catalyst. Has The Market Rerated Tarsus?
• Neutral Sentiment: HC Wainwright published a long‑range FY2030 estimate note (forward view) — informative for modeling but less impactful than near‑term revisions. FY2030 Estimate Issued
• Negative Sentiment: HC Wainwright sharply cut near‑term EPS estimates across multiple quarters and lowered FY2026–FY2029/FY2030 projections, trimming expected near‑term profitability and reducing some of the previous upside assumptions — a material negative for short‑term earnings expectations. HC Wainwright Cuts Estimates
• Negative Sentiment: Zacks downgraded Tarsus from “strong‑buy” to “hold,” which can dampen momentum from the price‑target increases and signals more cautious near‑term analyst conviction. Zacks Downgrade

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.